

5-5-2022

Case Report of Rare Mycobacterium Isolated from Mediastinal Abscess

Olivia Person

University of Nebraska Medical Center

Andrew S. Huang Pacheco

University of Nebraska Medical Center

Hana Niebur

University of Nebraska Medical Center

Melissa Suh

Boys Town National Research Hospital

Kari Neemann

University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/chri_forum

Recommended Citation

Person, Olivia; Huang Pacheco, Andrew S.; Niebur, Hana; Suh, Melissa; and Neemann, Kari, "Case Report of Rare Mycobacterium Isolated from Mediastinal Abscess" (2022). *Child Health Research Institute Pediatric Research Forum*. 58.

https://digitalcommons.unmc.edu/chri_forum/58

This Presentation is brought to you for free and open access by the Children's Hospital & Medical Center at DigitalCommons@UNMC. It has been accepted for inclusion in Child Health Research Institute Pediatric Research Forum by an authorized administrator of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.

Case Report of Rare Mycobacterium Isolated from Mediastinal Abscess

Olivia Person BS¹, Andrew S. Huang Pacheco MD², Hana Niebur MD FAAAAI³, Melissa Suh MD⁴, Kari Neemann MD⁵

1 College of Medicine, University of Nebraska Medical Center, 2 Division of Gastroenterology, Department of Pediatrics, University of Nebraska Medical Center, 3 Division of Pediatric Allergy/Immunology, Department of Pediatrics, University of Nebraska Medical Center, 4 Pediatric General and Thoracic Surgery, Boys Town National Research Hospital, 5 Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Nebraska Medical Center

Introduction

Mycobacterium arupense, a member of the *Mycobacterium terrae* complex identified in 2016, rarely causes infections despite isolation from multiple environmental sources, including water, soil and fish tanks.¹ Case reports have described tenosynovitis, osteomyelitis and disseminated infection in an immunocompromised host.¹⁻³ Here we describe a case of *M. arupense* identified in a polymicrobial mediastinal abscess in a pediatric patient subsequently diagnosed with autosomal dominant hyper-IgE syndrome (AD-HIES).

Case Description

A 4-year-old female with a history of pneumonia, herpetic skin infection, orbital cellulitis, and eczema presented in respiratory distress with concern for pneumonia. Imaging revealed a posterior mediastinal abscess which was drained on Day 3. Blood cultures identified *Streptococcus anginosus*, and the abscess fluid grew *Streptococcus anginosus*, *Streptococcus mitis/oralis* and *Candida albicans*. An esophagram and esophagogastroduodenoscopy revealed an esophageal sinus opening and fistula draining into the mediastinal abscess. After surgical closure, the fistula recurred, and an esophageal wound vacuum assisted closure (VAC) was placed. On Day 25, the initial acid-fast bacillus (AFB) abscess culture became positive, and ethambutol, rifampin, azithromycin and amikacin were started. The AFB was identified as *M. arupense*, and treatment was modified to clarithromycin, rifabutin, and ethambutol. Her course was complicated by drug-induced neutropenia and transaminitis. She received in total 61 days of antifungal, 58 days of antibacterial, and 40 days of *M. arupense* coverage. Due to the atypical infection, immune evaluation was performed and demonstrated low Th17 lymphocytes. Genetic testing detected a heterozygous pathogenic missense variant in *STAT3* (c.2141C>T) consistent with AD-HIES.

Discussion

This is the first case report of *M. arupense* isolated from a mediastinal abscess. Most *M. arupense* infections are secondary to direct inoculation injuries with resulting tenosynovitis and osteomyelitis.^{1,3} It is recognized as a possible respiratory tract colonizer, and therefore must meet clinical and microbiological criteria for diagnosis of NTM pulmonary disease.^{4,5} Limited susceptibility data has shown 97.5-100% of isolates susceptible to clarithromycin, ethambutol, and rifabutin.³ Empiric therapy with these three drugs is recommended pending susceptibility data. Treatment duration data is limited but adequate source control is needed as shown here. Evaluation of inborn errors of immunity should be considered in atypical and severe infections, which led to the diagnosis of AD-HIES. AD-HIES due to dominant-negative mutations in *STAT3* is characterized by elevated IgE, eczema, connective tissue and skeletal abnormalities, vascular malformations, and recurrent skin and pulmonary infections.^{6,7} Loss of *STAT3* activation and Th17 response underlies our subject's susceptibility to mycobacterial disease.⁸

References

1. Abudaff NN, Beam E. Mycobacterium arupense: A review article on an emerging potential pathogen in the Mycobacterium terrae complex. *J Clin Tuberc Other Mycobact Dis.* 2017;10:1-5. Published 2017 Nov 22. Doi:10.1016/j.jctube.2017.11.001
2. Heidarieh P, Hashemi-Shahraki A, Khosravi AD, Zaker-Boustanabad S, Shojaei H, Feizabadi MM. Mycobacterium arupense infection in HIV-infected patients from Iran. *Int J STD AIDS.* 2013 Jun;24(6):485-7. Doi: 10.1177/0956462412472818. Epub 2013 Jul 1. PMID: 23970753.
3. Beam E, Vasoo S, Simner PJ, et al. Mycobacterium arupense flexor tenosynovitis: case report and review of antimicrobial susceptibility profiles for 40 clinical isolates. *J Clin Microbiol.* 2014;52(7):2706-2708. Doi:10.1128/JCM.00277-14
4. Al Hamal Z, Jordan M, Hachem RY, et al. Mycobacterium arupense in Cancer Patients: An Emerging Infection or a Commensal Organism. *Medicine (Baltimore).* 2016;95(14):e2691. Doi:10.1097/MD.0000000000002691
5. Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, Böttger EC, Brozek J, Griffith DE, Guglielmetti L, Huitt GA, Knight SL, Leitman P, Marras TK, Olivier KN, Santin M, Stout JE, Tortoli E, van Ingen J, Wagner D, Winthrop KL. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. *Eur Respir J.* 2020 Jul 7;56(1):2000535. Doi: 10.1183/13993003.00535-2020. PMID: 32636299; PMCID: PMC8375621.
6. Freeman AF, Holland SM. The hyper-IgE syndromes. *Immunol Allergy Clin North Am.* 2008;28(2):277-viii. Doi:10.1016/j.iac.2008.01.005
7. Gernez Y, et al. Autosomal Dominant Hyper-IgE Syndrome in the USIDNET Registry. *J Allergy Clin Immunol Pract.* 2018 May-Jun; 6(3):996-1001. Doi: 10.1016/j.jaip.2017.06.041. PMID: 28939137; PMCID: PMC5858974.
8. Shen H, Chen ZW. The crucial roles of Th17-related cytokines/signal pathways in *M. tuberculosis* infection. *Cell Mol Immunol.* 2018;25:216-225. Doi: 10.1038/cmi.2017.128